Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Phase III Lasmiditan Data Strengthens Lilly's Dual Migraine Strategy

Aug 05 2017

• By Mandy Jackson

Human brain illustrated with millions of small nerves - Conceptual 3d render

Related Content

Amgen Beats Consensus, Raises Earnings Guidance, But Is It Sustainable?

Jul 26 2017

Lilly Pays Nearly $1bn To Regain Migraine Candidate It Once Sold For $1m

Jan 19 2017

CoLucid Hopes Lasmiditan Can Offer New, Safer Migraine Drug Class

Sep 07 2016

Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market

May 09 2017

Lilly Breathing Down Amgen/Novartis's Necks With Three Phase III Migraine Wins

May 12 2017

Allergan Focuses On Aesthetics As Sales Dip For Dry Eye Leader Restasis

Aug 04 2017

Pipeline Watch: Phase II Readouts With SPK-8011, Velusetrag, GBR-830

Aug 04 2017

Related Companies

Eli Lilly and Company

CoLucid Pharmaceuticals, Inc.

Amgen, Inc.

Novartis AG

Allergan plc

Biohaven Pharmaceutical Holding Company Ltd.

Additional Topics

Clinical Trials Business Strategies Drug Safety Research & Development Neurology BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window